-
1
-
-
72149108443
-
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
-
Bushby, K, Finkel, R, Birnkrant, DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9 (2010), 77–93.
-
(2010)
Lancet Neurol
, vol.9
, pp. 77-93
-
-
Bushby, K.1
Finkel, R.2
Birnkrant, D.J.3
-
2
-
-
41749096186
-
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
-
CD003725.
-
Manzur, AY, Kuntzer, T, Pike, M, Swan, A, Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev, 1, 2008 CD003725.
-
(2008)
Cochrane Database Syst Rev
, vol.1
-
-
Manzur, A.Y.1
Kuntzer, T.2
Pike, M.3
Swan, A.4
-
3
-
-
0036895043
-
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation
-
Eagle, M, Baudouin, SV, Chandler, C, Giddings, DR, Bullock, R, Bushby, K, Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12 (2002), 926–929.
-
(2002)
Neuromuscul Disord
, vol.12
, pp. 926-929
-
-
Eagle, M.1
Baudouin, S.V.2
Chandler, C.3
Giddings, D.R.4
Bullock, R.5
Bushby, K.6
-
4
-
-
84873020912
-
Ataluren as an agent for therapeutic nonsense suppression
-
Peltz, SW, Morsy, M, Welch, EM, Jacobson, A, Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64 (2013), 407–425.
-
(2013)
Annu Rev Med
, vol.64
, pp. 407-425
-
-
Peltz, S.W.1
Morsy, M.2
Welch, E.M.3
Jacobson, A.4
-
5
-
-
34247588271
-
PTC124 targets genetic disorders caused by nonsense mutations
-
Welch, EM, Barton, ER, Zhuo, J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007), 87–91.
-
(2007)
Nature
, vol.447
, pp. 87-91
-
-
Welch, E.M.1
Barton, E.R.2
Zhuo, J.3
-
6
-
-
84892581676
-
Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy
-
Finkel, RS, Flanigan, KM, Wong, B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy. PLoS One, 8, 2013, e81302.
-
(2013)
PLoS One
, vol.8
, pp. e81302
-
-
Finkel, R.S.1
Flanigan, K.M.2
Wong, B.3
-
7
-
-
84927669185
-
Ataluren treatment of patients with nonsense mutation dystrophinopathy
-
Bushby, K, Finkel, R, Wong, B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50 (2014), 477–487.
-
(2014)
Muscle Nerve
, vol.50
, pp. 477-487
-
-
Bushby, K.1
Finkel, R.2
Wong, B.3
-
8
-
-
79955618736
-
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
-
Pichavant, C, Aartsma-Rus, A, Clemens, PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 19 (2011), 830–840.
-
(2011)
Mol Ther
, vol.19
, pp. 830-840
-
-
Pichavant, C.1
Aartsma-Rus, A.2
Clemens, P.R.3
-
9
-
-
84919625145
-
European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
-
Haas, M, Vlcek, V, Balabanov, P, et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 25 (2015), 5–13.
-
(2015)
Neuromuscul Disord
, vol.25
, pp. 5-13
-
-
Haas, M.1
Vlcek, V.2
Balabanov, P.3
-
10
-
-
85032283237
-
Timed function tests and other physical function outcomes in ataluren-treated patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
-
McDonald, C, Reha, A, Elfring, G, Peltz, SW, Spiegel, R, Timed function tests and other physical function outcomes in ataluren-treated patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Neuromuscul Disord, 24, 2014, 861.
-
(2014)
Neuromuscul Disord
, vol.24
, pp. 861
-
-
McDonald, C.1
Reha, A.2
Elfring, G.3
Peltz, S.W.4
Spiegel, R.5
-
11
-
-
84976585919
-
Translarna summary of product characteristics
-
(accessed Oct 19, 2016).
-
European Medicines Agency. Translarna summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf (accessed Oct 19, 2016).
-
-
-
-
12
-
-
84910648036
-
PTC Therapeutics receives conditional approval in the European Union for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy
-
(accessed Oct 27, 2016).
-
PTC Therapeutics. PTC Therapeutics receives conditional approval in the European Union for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy. http://ir.ptcbio.com/releasedetail.cfm?releaseid=863914, 2014 (accessed Oct 27, 2016).
-
(2014)
-
-
-
13
-
-
84943188963
-
Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy
-
(accessed Oct 19, 2016).
-
European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199239.pdf, 2015 (accessed Oct 19, 2016).
-
(2015)
-
-
-
14
-
-
84992408411
-
Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment. Guidance for industry
-
(accessed Oct 19, 2016).
-
US Food and Drug Administration. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment. Guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM450229.pdf, 2015 (accessed Oct 19, 2016).
-
(2015)
-
-
-
15
-
-
84907487779
-
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes
-
Pane, M, Mazzone, ES, Sivo, S, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One, 9, 2014, e108205.
-
(2014)
PLoS One
, vol.9
, pp. e108205
-
-
Pane, M.1
Mazzone, E.S.2
Sivo, S.3
-
16
-
-
77957748915
-
North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy
-
Mazzone, E, Martinelli, D, Berardinelli, A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20 (2010), 712–716.
-
(2010)
Neuromuscul Disord
, vol.20
, pp. 712-716
-
-
Mazzone, E.1
Martinelli, D.2
Berardinelli, A.3
-
17
-
-
84894248468
-
Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy
-
Pane, M, Mazzone, ES, Fanelli, L, et al. Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 24 (2014), 201–206.
-
(2014)
Neuromuscul Disord
, vol.24
, pp. 201-206
-
-
Pane, M.1
Mazzone, E.S.2
Fanelli, L.3
-
18
-
-
84975758236
-
Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort
-
Willcocks, RJ, Rooney, WD, Triplett, WT, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann Neurol 79 (2016), 535–547.
-
(2016)
Ann Neurol
, vol.79
, pp. 535-547
-
-
Willcocks, R.J.1
Rooney, W.D.2
Triplett, W.T.3
-
19
-
-
85032268559
-
Developing skeletal muscle MRI/MRS as a biomarker for DMD therapeutic development
-
(accessed Sept 22, 2016).
-
Sweeney, L, Vandenborne, K, Developing skeletal muscle MRI/MRS as a biomarker for DMD therapeutic development. http://www.parentprojectmd.org/site/DocServer/Session_8_-_Sweeney_b.pdf?docID=15384 (accessed Sept 22, 2016).
-
-
-
Sweeney, L.1
Vandenborne, K.2
-
20
-
-
84883055833
-
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study
-
McDonald, CM, Henricson, EK, Abresch, RT, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48 (2013), 343–356.
-
(2013)
Muscle Nerve
, vol.48
, pp. 343-356
-
-
McDonald, C.M.1
Henricson, E.K.2
Abresch, R.T.3
-
21
-
-
0029374372
-
Profiles of neuromuscular diseases. Duchenne muscular dystrophy
-
McDonald, CM, Abresch, RT, Carter, GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 74 (1995), S70–S92.
-
(1995)
Am J Phys Med Rehabil
, vol.74
, pp. S70-S92
-
-
McDonald, C.M.1
Abresch, R.T.2
Carter, G.T.3
-
22
-
-
77950210043
-
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy
-
McDonald, CM, Henricson, EK, Han, JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41 (2009), 500–510.
-
(2009)
Muscle Nerve
, vol.41
, pp. 500-510
-
-
McDonald, C.M.1
Henricson, E.K.2
Han, J.J.3
-
23
-
-
84883050768
-
The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study
-
McDonald, CM, Henricson, EK, Abresch, RT, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48 (2013), 357–368.
-
(2013)
Muscle Nerve
, vol.48
, pp. 357-368
-
-
McDonald, C.M.1
Henricson, E.K.2
Abresch, R.T.3
-
24
-
-
84862004315
-
Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy
-
Scott, E, Eagle, M, Mayhew, A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 17 (2012), 101–109.
-
(2012)
Physiother Res Int
, vol.17
, pp. 101-109
-
-
Scott, E.1
Eagle, M.2
Mayhew, A.3
-
25
-
-
84958863314
-
The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
-
Ricotti, V, Ridout, DA, Pane, M, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87 (2016), 149–155.
-
(2016)
J Neurol Neurosurg Psychiatry
, vol.87
, pp. 149-155
-
-
Ricotti, V.1
Ridout, D.A.2
Pane, M.3
-
26
-
-
79956006620
-
Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy
-
Mayhew, A, Cano, S, Scott, E, Eagle, M, Bushby, K, Muntoni, F, Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 53 (2011), 535–542.
-
(2011)
Dev Med Child Neurol
, vol.53
, pp. 535-542
-
-
Mayhew, A.1
Cano, S.2
Scott, E.3
Eagle, M.4
Bushby, K.5
Muntoni, F.6
-
27
-
-
84885183817
-
Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy
-
Mayhew, AG, Cano, SJ, Scott, E, et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 55 (2013), 1046–1052.
-
(2013)
Dev Med Child Neurol
, vol.55
, pp. 1046-1052
-
-
Mayhew, A.G.1
Cano, S.J.2
Scott, E.3
-
28
-
-
0031691511
-
The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity and sensitivity to change. Pediatric Outcomes Development Group. Pediatric Orthopaedic Society of America
-
Daltroy, LH, Fossel, AH, Goldberg, MJ, The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity and sensitivity to change. Pediatric Outcomes Development Group. Pediatric Orthopaedic Society of America. J Pediatr Orthop 18 (1998), 561–571.
-
(1998)
J Pediatr Orthop
, vol.18
, pp. 561-571
-
-
Daltroy, L.H.1
Fossel, A.H.2
Goldberg, M.J.3
-
29
-
-
0025031812
-
No adjustments are needed for multiple comparisons
-
Rothman, KJ, No adjustments are needed for multiple comparisons. Epidemiology 1 (1990), 43–46.
-
(1990)
Epidemiology
, vol.1
, pp. 43-46
-
-
Rothman, K.J.1
-
30
-
-
84940211391
-
Improving clinical trial design for Duchenne muscular dystrophy
-
Merlini, L, Sabatelli, P, Improving clinical trial design for Duchenne muscular dystrophy. BMC Neurol, 15, 2015, 153.
-
(2015)
BMC Neurol
, vol.15
, pp. 153
-
-
Merlini, L.1
Sabatelli, P.2
-
31
-
-
84901346395
-
A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy
-
Peay, HL, Hollin, I, Fischer, R, Bridges, JF, A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther 36 (2014), 624–637.
-
(2014)
Clin Ther
, vol.36
, pp. 624-637
-
-
Peay, H.L.1
Hollin, I.2
Fischer, R.3
Bridges, J.F.4
-
32
-
-
84879902003
-
The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year
-
ecurrents.md.9e17658b007eb79fcd6f723089f79e06.
-
Henricson, E, Abresch, R, Han, JJ, et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr, 5, 2013 ecurrents.md.9e17658b007eb79fcd6f723089f79e06.
-
(2013)
PLoS Curr
, vol.5
-
-
Henricson, E.1
Abresch, R.2
Han, J.J.3
|